Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biofrontera (BFRI) Operating Expenses (2020 - 2025)

Biofrontera has reported Operating Expenses over the past 6 years, most recently at $12.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 12.12% year-over-year to $12.5 million; the TTM value through Dec 2025 reached $53.1 million, down 2.72%, while the annual FY2025 figure was $53.1 million, 2.71% down from the prior year.
  • Operating Expenses for Q4 2025 was $12.5 million at Biofrontera, down from $13.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $20.4 million in Q3 2021 and troughed at $8.0 million in Q3 2022.
  • A 5-year average of $13.0 million and a median of $13.3 million in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: soared 265.24% in 2021 and later plummeted 61.05% in 2022.
  • Year by year, Operating Expenses stood at $11.0 million in 2021, then surged by 42.69% to $15.8 million in 2022, then dropped by 8.27% to $14.5 million in 2023, then dropped by 1.31% to $14.3 million in 2024, then fell by 12.12% to $12.5 million in 2025.
  • Business Quant data shows Operating Expenses for BFRI at $12.5 million in Q4 2025, $13.3 million in Q3 2025, and $14.1 million in Q2 2025.